Tokyo Tape
Sign in
← GNI Group

Half-year report · Q2

2160.TEDINET S100U8GV
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥11.7bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥5.8bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥26.0bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥14.1bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥9.9bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥1.8bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥522m2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥5.5bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥5.1bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥831m2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥996m2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥12.6bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥5.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.2bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥330m2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥1.1bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.1bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.7bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.7bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥74m2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income−¥1.4bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥9.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥4.0bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥4.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥69.0bnat 2024-06-30Cons.Assets IFRS
Total assets¥62.4bnat 2023-12-31Cons.Assets IFRS
Total assets¥45.1bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.4bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥26.3bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥39.6bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥36.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥24.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥36.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥33.8bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥23.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥16.3bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥872m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥6.8bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥186m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥10.7bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥6.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-22.492024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥169.52023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.932023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥34.992023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥6.372024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-22.492024-04-01 → 2024-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥165.562023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.812023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥34.882023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.4%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio54.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio51.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2024-01-01 → 2024-06-30¥676m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2024-01-01 → 2024-06-30¥1.1bn
—segment totalrevenue2024-01-01 → 2024-06-30¥11.7bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥11.7bn
—segment totalsegment profit2024-01-01 → 2024-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-06-30¥1.3bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-06-30¥512m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-06-30¥5.0bn
—segment totalrevenue2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥23m
—segment totalsegment profit2023-01-01 → 2023-06-30¥5.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 740
ItemContextValueUnit
Operating profit loss IFRSPrior1YTDDuration5476475000JPY
Finance income IFRSPrior1YTDDuration306524000JPY
Finance costs IFRSPrior1YTDDuration539038000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-126000000JPY
Profit loss before tax IFRSPrior1YTDDuration5117961000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember9145014000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember2588807000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember11733821000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration11733821000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember9145014000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember2588807000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember11733821000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue IFRSCurrentYTDDuration11733821000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember1086200000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember675942000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember1762142000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSCurrentYTDDuration1762142000JPY
Finance income IFRSCurrentYTDDuration371879000JPY
Finance costs IFRSCurrentYTDDuration1343366000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration40735000JPY
Profit loss before tax IFRSCurrentYTDDuration831391000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-08-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第24期中（自　2024年１月１日　至　2024年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社ジーエヌアイグループ
Company name in english cover pageFilingDateInstantGNI Group Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)取締役代表執行役社長兼CEO　　イン・ルオ
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目２番２号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03（6214）3600（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役執行役CFO　　北川　智哉
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目２番２号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03（6214）3600（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役執行役CFO　　北川　智哉
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05712
Fund codeFilingDateInstant－
Security codeFilingDateInstant21600
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社ジーエヌアイグループ
Filer name in englishFilingDateInstantGNI Group Ltd.
Fund name in japaneseFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass